Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
jRCT1011220040Not yet recruiting
Open-label, single-arm trial of sevoflurane in brain neoplasm and cerebrovascular disease. Primary endpoint: Rate of successful MEP monitoring. Planned start Feb 2023; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on jRCT1011220040.